Common class of diabetes drugs could also be protecting in opposition to glaucoma

A preferred class of diabetes drugs referred to as GLP-1R agonists (Trulicity and Rybelsus) may defend in opposition to glaucoma in diabetic sufferers, in line with a brand new research led by researchers within the Scheie Eye Institute on the College of Pennsylvania’s Perelman College of Drugs. The findings had been revealed within the British Journal of Ophthalmology.

The researchers checked out retrospective knowledge of 1,961 diabetic sufferers who had been new customers of this class of medication and matched them to 4,371 unexposed management topics. After 150 days on common, 10 sufferers within the medicated group had been newly identified with glaucoma (0.5 %) in comparison with 58 sufferers (1.3 %) within the management group. The findings recommend that GLP-1 receptor agonists might lower a diabetic affected person’s threat of creating glaucoma by half.

The findings are supported by a Penn Drugs research from 2020, which discovered that GLP-1R agonists lowered neuroinflammation and prevented retinal ganglion cell loss of life in mice. This class of medication has additionally proven equally protecting results in opposition to Alzheimer’s and Parkinson’s illnesses in animal fashions, and medical trials are underway to check the drugs in opposition to neurodegenerative illnesses in people.

Glaucoma impacts 3 million Individuals and is the second main reason behind blindness worldwide. Folks with diabetes are twice as more likely to develop the attention situation.

It was very encouraging to see {that a} standard diabetes treatment may considerably scale back the danger of creating glaucoma, and our research means that these drugs warrant additional research on this affected person inhabitants.”


Qi N. Cui, MD, PhD, and Brian VanderBeek, MD, MPH, Assistant Professors of Ophthalmology at Penn

Supply:

College of Pennsylvania

Journal reference:

Sterling, J., et al. (2021) Glucagon-like peptide 1 receptor agonist use is related to lowered threat for glaucoma. British Journal of Ophthalmology. doi.org/10.1136/bjophthalmol-2021-319232.

#Common #class #diabetes #drugs #protecting #glaucoma